Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Other Accumulated Expenses (2016 - 2024)

Jaguar Health (JAGX) has disclosed Other Accumulated Expenses for 8 consecutive years, with $661000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Other Accumulated Expenses fell 67.23% to $661000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $661000.0, a 67.23% decrease, with the full-year FY2024 number at $661000.0, down 67.23% from a year prior.
  • Other Accumulated Expenses was $661000.0 for Q4 2024 at Jaguar Health, down from $2.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.0 million in Q4 2023 to a low of $9000.0 in Q4 2022.
  • A 4-year average of $743000.0 and a median of $473000.0 in 2021 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 96.84% in 2022, then surged 22311.11% in 2023.
  • Jaguar Health's Other Accumulated Expenses stood at $285000.0 in 2021, then crashed by 96.84% to $9000.0 in 2022, then soared by 22311.11% to $2.0 million in 2023, then plummeted by 67.23% to $661000.0 in 2024.
  • Per Business Quant, the three most recent readings for JAGX's Other Accumulated Expenses are $661000.0 (Q4 2024), $2.0 million (Q4 2023), and $9000.0 (Q4 2022).